Ideaya Biosciences (IDYA) announced that it has dosed the first patient in the Ideaya-sponsored Phase 1 trial evaluating the combination of IDE161, the company’s investigational small molecule poly glycohydrolase, or PARG, inhibitor, in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda, in endometrial cancer patients with high microsatellite instability and microsatellite stable.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IDYA:
- Ideaya Biosciences nominates IDE892 as development candidate
- Ideaya Biosciences initiated with an Overweight at Stephens
- Ideaya Biosciences appoints Stu Dorman as chief commercial officer
- Ideaya Biosciences nominates IDE034 as development candidate, exercises option
- Biocytogen announces Ideaya’s nomination of development candidate IDE034
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
